Incyte Corporation (NASDAQ:INCY) [Trend Analysis] retains strong position in active trade, as shares scoring 2.69% to $104.76 in a active trade session, while looking at the shares volume, around 1.79 Million shares have changed hands in this session. Incyte reports 5-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials; long-term treatment with Jakafi prolonged survival compared to controls (INCY). The firm announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall survival findings and suggests that earlier treatment with Jakafi may result in an improved survival advantage for patients with intermediate-2 or high-risk myelofibrosis than best available therapy or placebo.
These data also reinforce previous long-term results observed with ruxolitinib compared with controls. At the five-year intent-to-treat analysis, 42.5% of the patients randomized to the ruxolitinib group died compared with 51.5% of the patients randomized to the control group. The firm has institutional ownership of 96.80%, while insider ownership included 0.50%. INCY attains analyst recommendation of 1.70 with week’s performance of -0.39%. Investors looking further ahead will note that the Price to next year’s EPS is 143.39%.
Johnson Controls International plc (NYSE:JCI) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -1.52% to 44.63 with around 6.49 Million shares have changed hands in this session. Johnson Controls International, plc (JCI) announced its fiscal 2017 EPS before special items guidance of $2.60 to $2.75 per share, a 13 percent to 19 percent year-over-year increase, compared to the pro forma fiscal 2016 base of $2.31 per share. Guidance includes an organic revenue growth range of 2.5 percent to 4.5 percent and EBIT margin expansion before special items of 80 to 110 basis points.
Johnson Controls also introduced mid-term financial targets covering the fiscal years through 2020: 12 to 15 percent growth in EPS before special items CAGR; 3 to 4 percent growth in organic revenue CAGR including $500 million in run-rate sales synergies; 40 to 55 percent EBIT growth before special items with 300 to 380 basis points of margin expansion; approximately $1 billion of productivity/merger cost savings plus $150 million of tax synergies; and FCF conversion target of 90 percent+ before special items. The stock is going forward its fifty-two week low with 56.62% and lagging behind from its 52-week high price with -8.86%.
Similar, the positive performance for the quarter recorded as -8.73% and for the year was 34.37%, while the YTD performance remained at 43.09%. JCI has Average True Range for 14 days of 0.96.